Difluprednate for the prevention of ocular inflammation postsurgery: An update

Clinical Ophthalmology

Volumn 5, Issue 1, 2011, Pages 811-816

  Donnenfeld, Eric D ^a  

^a OPHTHALMIC CONSULTANTS OF LONG ISLAND   (United States)

Author keywords

Anti inflammatory; Corticosteroids; Dose uniformity; Relative potency

Indexed keywords

BETAMETHASONE; DIFLUPREDNATE; PREDNISOLONE; PREDNISOLONE ACETATE; TRIAMCINOLONE;

ANTIINFLAMMATORY ACTIVITY; DIABETIC MACULAR EDEMA; DOSE UNIFORMITY; DRUG EFFICACY; DRUG POTENCY; DRUG PULSE THERAPY; DRUG RECEPTOR BINDING; DRUG SAFETY; EMULSION; EYE INFLAMMATION; HUMAN; INTRAOCULAR PRESSURE; PHARMACOLOGICAL PARAMETERS; POSTERIOR EYE SEGMENT; POSTOPERATIVE CARE; POSTOPERATIVE INFLAMMATION; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; SUSPENSION;

EID: 79959832744     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: 10.2147/OPTH.S6541     Document Type: Review

References (16)

1. El-Harazi SM, Feldman RM. Control of intra-ocular inflammation associated with cataract surgery. Curr Opin Ophthalmol. 2001;12(1): 4-8.
2. Durezol® (difluprednate ophthalmic emulsion, 0.05%) Package Insert Alcon Laboratories, Inc, Fort Worth, TX.
3. Apt I, Hendrick A, Silverman L. Patient compliance with use of topical ophthalmic corticosteroid suspensions. Am J Ophthalmol. 1979; 87(2):210-214.
4. Stringer W, Bryant R. Dose uniformity of topical corticosteroid preparations: difluprednate ophthalmic emulsion 0.05% versus branded and generic prednisolone acetate ophthalmic suspension 1%. Clin Ophthalmol. 2010;5(4):1119-1124.
5. Tajika T, Waki M, Tsuzuki M, Kida T, Sakaki H. Pharmacokinetic features of difluprednate ophthalmic emulsion in rabbits as determined by glucocorticoid receptor-binding bioassay. J Ocul Pharmacol Ther. 2011;27(1):29-34.
6. Bush IE, Mahesh VB. Metabolism of 11-oxygenated steroids. 3. Some 1-dehydro and 9 alpha-fluoro steroids. Biochem J. 1964;93(2):236-255.
7. Sytkowski A, Shetty KR. Relating corticosteroid structure and function. Drug Ther. 1975;143-148.
8. Bartlett JD, Bennett ES, Fiscella RG, Jaanus SD, Zimmerman TJ. Ophthalmic Drug Facts. 19 ed. St Louis, MO:Wolters Kluwer; 2008.
9. Hammer S, Spika I, Sippl W, et al. Glucocorticoid receptor interactions with glucocorticoids: evaluation by molecular modeling and sdfsdf functional analysis of glucocorticoid receptor mutants. Steroids. 2003; 68(4):329-339.
10. Holte K, Kehlet H. Perioperative single-dose glucocorticoid administration: pathophysiologic effects and clinical implications. J Am Coll Surg. 2002;195(5):694-712.
11. Bracken MB, Shepard MJ, Holford TR, et al. Methylprednisolone or tirilazadmesylate administration after acute spinal cord injury: 1-year follow up. Results of the third National Acute Spinal Cord Injuryrandomized controlled trial. J Neurosurg. 1998;89(5):699-706.
12. Donnenfeld ED, Holland EJ, Solomon KD, et al. A multicenter randomized controlled fellow eye trial of pulse dosed difluprednate 0.05% versus prednisolone acetate 1% in cataract surgery. Am J Ophthalmol. In press 2011.
13. Foster CS, Davanzo R, Flynn TE, McLeod K, Vogel R, Crockett RS. Durezol® (difluprednate ophthalmic emulsion 0.05%) compared with Pred Forte® 1% ophthalmic suspension in the treatment of endogenous anterior uveitis. J Ocul Pharmacol Ther. 2010;26(5):475-483.
14. Tajika T, Isowaki A, Sakaki H. Ocular distribution of difluprednate ophthalmic emulsion 0.05% in rabbits. J Ocul Pharmacol Ther. 2011; 27(1):43-49.
15. Nakano S, Yamamoto T, Kirii E, Abe S, Yamashita H. Steroid eye drop treatment (difluprednate ophthalmic emulsion) is effective in reducing refractory diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2010;248(6):805-810.
16. Nakano Goto S, Yamamoto T, Kirii E, Abe S, Yamashita H. Treatment of diffuse diabetic macular oedema using steroid eye drops. Acta Ophthalmol.[Epub ahead of press].